Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics

Schalkwijk, Casper G.; Miyata, Toshio

doi:10.1007/s00726-010-0779-9

Cited by 108 publications

(72 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nonenzymatic glycation of proteins or Maillard reaction is increased in diabetes mellitus due to hyperglycemia (Hussain et al, 2008;Cárdenas-León et al, 2009;Hussain et al, 2010;Hussain et al, 2011;Schalkwijk, Miyata, 2012). Numerous synthetic and natural com- pounds with different glycation inhibition mechanisms are reviewed in literature.…”

Section: Discussionmentioning

confidence: 99%

Determination of in vitro antidiabetic effects of Zingiber officinale Roscoe

Sattar

Hussain

Iqbal

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

Aqueous extracts of Zingiber officinale rhizomes were studied to evaluate their antidiabetic effects on protein glycation and on the diffusion of glucose in vitro in the present study. Zingiber officinale rhizome aqueous extract were examined at concentrations of 5, 10, 20 and 40 g/L. The antidiabetic effects were found to be dose-dependent. Antidiabetic potential of Zingiber officinale was mainly through inhibition of the glucose diffusion and to a limited extent by reducing the glycation. However, further studies are needed to determine in vitro effects of therapeutic potential by restraining postprandial glucose absorptions and plasma protein glycations in diabetic subjects.Uniterms: Zingiber officinale/pharmacognosy. Zingiber officinale/antidiabetic effects/in vitro study. Diabetes mellitus. Hyperglycemia. Proteins/glycation. Glucose/diffusion in vitro.Extratos aquosos de rizomas Zingiber officinale foram estudados para avaliar os seus efeitos antidiabéticos em glicação de proteínas e sobre a difusão de glicose in vitro, no presente estudo. Extratos aquosos de Zingiber officinale foram examinados nas concentrações de 5, 10, 20 e 40 g extrato de planta/L. Os efeitos antidiabéticos observados eram dependentes da dose. O potencial antidiabético de Zingiber officinale se verificou, principalmente, através da inibição da difusão de glicose e, em menor extensão, através da redução da glicação. Estudos adicionais são necessários para elucidar se efeitos in vitro representam potencial terapêutico, restringindo a absorção de glicose pós-prandial e a glicação de proteínas plasmáticas em indivíduos diabéticos. Unitermos:Zingiber officinale/farmacognosia. Zingiber officinale/efeitos antidiabéticos/estudo in vitro. Diabetes mellitus. Hiperglicemia. Proteinas/glicação. Glicose/difusão in vitro.

show abstract

Section: Discussionmentioning

confidence: 99%

Determination of in vitro antidiabetic effects of Zingiber officinale Roscoe

Sattar

Hussain

Iqbal

et al. 2012

Braz. J. Pharm. Sci.

View full text Add to dashboard Cite

show abstract

“…Various studies have reported that the renal accumulation of AGEs is implicated in the pathogenesis of diabetic vascular complications [52] . As well, AGEs are noted to upregulate the expression of TGF-β and collagen, which accumulates particularly in glomerular and extracellular matrix, thus provoking glomerular hypertrophy in diabetes [53] .…”

Section: Tgf-β Plays An Abysmal Role In Pathogenesis Of Nephropathy: mentioning

confidence: 99%

Smoking in diabetic nephropathy: sparks in the fuel tank?

Chakkarwar¹

2012

WJD

View full text Add to dashboard Cite

Diabetic nephropathy is associated with high morbidity and mortality and the prevalence of this disease is continuously increasing worldwide. Long-term diabetes increases the likelihood of developing secondary complications like nephropathy, the most common cause of end stage renal disease. Usually, other factors like hypertension, alcoholism and smoking also partly contribute to the progression of diabetic nephropathy. Among this, cigarette smoking in diabetes has been repeatedly confirmed as an independent risk factor for the onset and progression of diabetic nephropathy. Various studies suggest that smoking is a major fuel in the development of high oxidative stress and subsequently hyperlipidemia, accumulation of advanced glycation end products, activation of the renin angiotensin system and Rho-kinase, which are observed to play a pathogenic role in the progression of diabetic nephropathy. Furthermore, cigarette smoking in diabetic patients with vascular complications produces a variety of pathological changes in the kidney, such as thickening of the glomerular basement membrane and mesangial expansion with progression in glomerulosclerosis and interstitial fibrosis, which ultimately results in end stage renal failure. Strong associations are consistently found between chronic cigarette smoking and diabetic microvascular complications. A diverse group of studies unveil potential mechanisms that may explain the role of cigarette smoking in the progression of diabetic nephropathy. Tremendous efforts are being made to control smoking mediated progression of diabetic nephropathy, but no promising therapy is yet available. The present review critically discusses the possible detrimental role of chronic cigarette smoking in the progression of diabetic nephropathy and various possible pharmacological interventions to attenuate the exacerbation of diabetic nephropathy.

show abstract

“…The renowned deleterious effects of AGEs on endothelial function and vessel structure has prompted numerous studies on molecules with promising blocking effects on AGE formation and AGE-receptor (RAGE)-mediated activity, or acting to prevent or disrupt AGEprotein cross-links (reviewed in [192][193][194]). Aminoguanidine is able to inhibit the formation of AGEs by interaction with and quenching of dicarbonyl compounds.…”

Section: Age Inhibitors -mentioning

confidence: 99%

Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options

Potenza

Nacci

Salvia

et al. 2017

Pharmacological Research

View full text Add to dashboard Cite

Abstract:The association of obesity and diabetes, termed "diabesity", defines a combination of primarily metabolic disorders with insulin resistance as the underlying common pathophysiology. Cardiovascular disorders associated with diabesity represent the leading cause of morbidity and mortality in the Western world. This makes diabesity, with its rising impacts on both health and economics, one of the most challenging biomedical and social threats of present century. The emerging comprehension of the genes whose alteration confers inter-individual differences on risk factors for diabetes or obesity, together with the potential role of genetically determined variants on mechanisms controlling responsiveness, effectiveness and safety of anti-diabetic therapy underlines the need of additional knowledge on molecular mechanisms involved in the pathophysiology of diabesity. Endothelial cell dysfunction, resulting from the unbalanced production of endothelialderived vascular mediators, is known to be present at the earliest stages of insulin resistance and obesity, and may precede the clinical diagnosis of diabetes by several years. Once considered as a mere consequence of metabolic abnormalities, it is now clear that endothelial dysfunctional activity may play a pivotal role in the progression of diabesity. In the vicious circle where vascular defects and metabolic disturbances worsen and reinforce each other, a low-grade, chronic, and 'cold' inflammation (metaflammation) has been suggested to serve as the pathophysiological link that binds endothelial and metabolic dysfunctions. In this paradigm, it is important to consider how traditional antidiabetic treatments (specifically addressing metabolic dysregulation) may directly impact on inflammatory processes or cardiovascular function. Indeed, not all drugs currently available to treat diabetes possess the same anti-inflammatory potential, or target endothelial cell function equally. Perspective strategies pointing at reducing metaflammation or directly addressing endothelial dysfunction may disclose beneficial consequences on metabolic regulation. This review focuses on existing and potential new approaches ameliorating endothelial dysfunction and vascular inflammation in the context of diabesity.

show abstract

Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics

Cited by 108 publications

References 117 publications

Determination of in vitro antidiabetic effects of Zingiber officinale Roscoe

Determination of in vitro antidiabetic effects of Zingiber officinale Roscoe

Smoking in diabetic nephropathy: sparks in the fuel tank?

Targeting endothelial metaflammation to counteract diabesity cardiovascular risk: Current and perspective therapeutic options

Contact Info

Product

Resources

About